Selective estrogen receptor modulator
Clomiphene (Clomid)
Clomiphene (Clomid) after one dose: 50% at ~7 days, 25% at 14 days, 12.5% at 21 days.
Drawn from the half-life in the app's model, ~7 days. The model's figures
- Compound
- Clomiphene (Clomid)
- Symbol
- CLO
- Family
- Post-cycle and ancillaries
- Parts
- 14
- References
- 19
- Checked
- Last reviewed . Sources are listed below.
Overview
Clomiphene citrate, sold as Clomid, is a mixture of two geometric isomers, cis (zuclomiphene) and trans (enclomiphene), containing between 30% and 50% of the cis-isomer.1 The label describes it as an orally administered, nonsteroidal, ovulatory stimulant and states its indication as the treatment of ovulatory dysfunction in women desiring pregnancy.1 The same label states: "There are no adequate or well-controlled studies that demonstrate the effectiveness of clomiphene citrate in the treatment of male infertility."1
Krzastek and colleagues wrote in the Journal of Urology in 2019 that clomiphene citrate "may be used as an off label treatment of hypogonadism".2 A 2025 meta-analysis of randomised trials in men with hypogonadism pooled clomiphene and enclomiphene trials.3 The World Anti-Doping Agency's 2026 Prohibited List names clomifene in class S4.2, anti-estrogenic substances, which is prohibited at all times.4
How it works
Sources in this part
What the label says
The label states that clomiphene citrate "is capable of interacting with estrogen-receptor-containing tissues, including the hypothalamus, pituitary, ovary, endometrium, vagina, and cervix" and "may compete with estrogen for estrogen-receptor-binding sites".1 It describes the first endocrine event in response to a course of clomiphene therapy as "an increase in the release of pituitary gonadotropins", which "initiates steroidogenesis and folliculogenesis".1 On the two isomers, the label states: "Some data suggest that zuclomiphene has greater estrogenic activity than enclomiphene."1
In men
Hohl and colleagues describe selective estrogen receptor modulators in men as antagonizing estrogen receptors in the hypothalamus, which increases the secretion of gonadotropin-releasing hormone and so stimulates endogenous testosterone production.3
Half-life and pharmacokinetics
Values from the Milligram app's model.
- Half-life
- ~7 days
- Bioavailability
- 95%
- Typical dose
- 10–50 mg/day
- Route
- Oral
- Time to peak
- ~4 h
The app's half-life figure for clomiphene is about 7 days (168 hours). The label states no half-life figure and gives only a comparison of the isomers: zuclomiphene has a longer half-life than enclomiphene, with detectable levels that "persisted for longer than a month" in normal volunteers.1
| Parameter | The app's figure | What the sources report |
|---|---|---|
| Half-life | ~7 days (168 hours) | The label gives no half-life figure.1 Ghobadi and colleagues (2009) wrote that the conventional model-dependent pharmacokinetics of the isomers "could not be determined due to a very flat terminal half-life and the long-tailed residence time" in 9 women with polycystic ovary syndrome after one 50 mg dose.5 Wiehle and colleagues (2013), whose authors include Repros Therapeutics staff, write in their discussion that enclomiphene citrate alone is known to have a serum half-life of about 7 hours.6 |
| Bioavailability (oral) | ~95% | No percentage is given in the label, which states that the drug "was shown to be readily absorbed orally in humans and excreted principally in the feces", with cumulative excretion of the 14C label averaging about 50% of an oral dose and 37% of an intravenous dose after 5 days.1 |
| Time to peak | ~4 hours | After one 50 mg dose, Ghobadi and colleagues reported a mean t(max) of 7 hours for zuclomiphene and 3 hours for enclomiphene (coefficients of variation 87% and 68%).5 Mikkelson and colleagues (1986) reported that in 24 healthy women the Z (cis) isomer "attained peak blood levels later than" the E (trans) isomer.7 |
| Metabolism | Not in the app | In human liver microsomes, CYP2D6 was identified as the major enzyme forming (E)-4-hydroxyclomiphene and (E)-4-hydroxy-N-desethylclomiphene, which showed the strongest inhibition of oestrogen receptor activity (50% inhibitory concentrations 2.5 and 1.4 nM); in a healthy female volunteer study their maximum concentrations were 8 and 12 times lower in subjects with non-functional CYP2D6 alleles.8 |
In 15 men aged 22 to 70 who had taken 25 mg of clomiphene daily for at least 6 weeks, Helo and colleagues (BJU International, 2017) measured median serum concentrations of 44.0 ng/mL for zuclomiphene and 2.2 ng/mL for enclomiphene, a median ratio of 20:1.9 Three of that study's authors list Repros Therapeutics as their affiliation, and the PubMed entry gives no funding statement.9
The chart uses the app's half-life of 168 hours and time to peak of 4 hours, which differ from the source figures above; the intervals shown are the ones two cited studies reported, daily dosing by Helo and colleagues in 2015 and every other day dosing by Katz and colleagues in 2012.10,11
Human studies
The studies fall into two groups: trials in women with ovulatory dysfunction, the label's population, and studies in men with hypogonadism, where use is off label.1,2
| Study and year | Design | People | Dose and length | Main result |
|---|---|---|---|---|
| Legro and colleagues, 200712 | Randomised, three arms with placebo; NICHD grants listed in the PubMed entry | 626 infertile women with polycystic ovary syndrome | Clomiphene citrate, metformin or both, up to 6 months | Live birth 22.5% (47 of 209) with clomiphene, 7.2% (15 of 208) with metformin, 26.8% (56 of 209) with both; multiple pregnancy 6.0% among pregnancies on clomiphene; clomiphene against the combination P = 0.31; adverse-event rates similar in all groups apart from pregnancy complications. |
| Legro and colleagues, 201413 | Randomised, double-blind, multicentre, against letrozole; NICHD-funded | 750 women with polycystic ovary syndrome, aged 18 to 40 | Clomiphene 50 mg daily for 5 days a cycle, up to 150 mg, up to 5 cycles | Live birth 72 of 376 (19.1%) with clomiphene against 103 of 374 (27.5%) with letrozole (P = 0.007); twin pregnancy 7.4% against 3.4%; hot flushes 33.0% against 20.3%. |
| Habous and colleagues, 201814 | Randomised, open-label, three arms, rated high risk of bias (randomisation) by Hohl3; no funding statement in the PubMed entry | 282 men with hypogonadism wishing to preserve fertility | Clomiphene 50 mg (n = 95), hCG 5000 IU twice weekly (n = 94) or both (n = 94), 3 months | Testosterone rose in all three groups (mean baseline 2.31 ± 0.66 nmol/L, final mean 5.17 ± 1.77 nmol/L, a 223% increase) with no significant difference among them; qADAM scores rose in all groups, with a significant difference for the combination against the other two (P < 0.01); Hohl reports testosterone higher with clomiphene and with the combination than with hCG alone (158, 153 and 134 ng/dL; p < 0.002)3. |
| Helo and colleagues, 201510 | Randomised, double-blind, against anastrozole, rated some concerns for bias by Hohl3; no funding statement in the PubMed entry | 26 infertile men with testosterone below 350 ng/dL and normal LH | Clomiphene 25 mg/day or anastrozole 1 mg/day, 12 weeks | Testosterone rose more with clomiphene (mean increase 571 against 408 ng/dL); estradiol rose with clomiphene, and the testosterone-to-estradiol ratio rose significantly only with anastrozole; neither group changed significantly in semen parameters or patient-reported outcomes. |
| Soares and colleagues, 201815 | Single-centre, randomised, double-blind, placebo-controlled; listed as research support, non-US government | 78 men aged 36.5 ± 7.8 years, BMI over 30 kg/m2, testosterone 300 ng/dL or less | Clomiphene 50 mg or placebo, 12 weeks | Increases in total and free testosterone, estradiol, LH, FSH and SHBG; improvement in one sexual complaint (weaker erections); improvements in lean mass, fat-free mass and muscle mass; HDL reduced; PSA rose within the normal range per Hohl3; no significant difference in endothelial function. |
| Pelusi and colleagues, 201716 | Crossover, randomised, double-blind, placebo-controlled; funded by an Italian research project; no competing interests declared; short treatment period named as a limitation | 24 obese men aged 35 to 55 with low testosterone and impaired glucose tolerance or type 2 diabetes; 21 evaluable | Clomiphene 25 mg/day or placebo, each with metformin 2 g/day, 3 months a period | Testosterone rose from 3.03 ± 0.80 to 5.99 ± 1.67 ng/mL on clomiphene and from 2.87 ± 0.78 to 3.09 ± 0.84 on placebo; LH and FSH rose on clomiphene. |
| Katz and colleagues, 201211 | Prospective case series; a Level of Evidence 4 per the authors; listed as research support, non-US government | 86 men with hypogonadism, mean age 29 | Clomiphene 25 mg every other day, titrated to 50 mg every other day; mean 19 months | All mean testosterone and gonadotropin measurements increased; ADAM questionnaire improved in all questions except loss of height; no major side effects recorded. |
| Krzastek and colleagues, 20192 | Retrospective, 2 institutions, 2010 to 2018; no funding statement in the PubMed entry | 400 men with hypogonadism (testosterone under 300 ng/dL) | Mean 25.5 ± 20.48 months (range 0 to 84); dose not stated in the PubMed entry | Of 120 men treated for more than 3 years, 88% reached eugonadism, 77% reported improved symptoms and 8% reported side effects (mood changes in 5, blurred vision in 3, breast tenderness in 2); estradiol rose; no significant adverse event in any patient. |
| Saffati and colleagues, 202417 | Retrospective, single academic centre; no funding; author consulting disclosures | 66 men who took clomiphene and later enclomiphene | Median 18.7 months on clomiphene, then 8.9 months on enclomiphene | Adverse effects in 47% on clomiphene and 13.8% on enclomiphene; testosterone change 98 against 166 ng/dL (P = 0.20); estradiol change 17.5 against −5.92 pg/mL (P = 0.001). |
| Hohl and colleagues, 20253 | Meta-analysis of randomised trials; clomiphene and enclomiphene pooled | 10 studies, 819 men with testosterone of 300 ng/dL or less | Follow-up 2 to 30 weeks | Against placebo, total testosterone rose by a mean difference of 273.76 ng/dL (95% CI 191.87 to 355.66; I2 = 89%); sperm concentration did not differ significantly. |
Deeper analysis: Legro and colleagues, 2014
Legro and colleagues for the NICHD Reproductive Medicine Network reported the trial in the New England Journal of Medicine in 2014, with clomiphene as one of the two randomised treatments.13 In this double-blind, multicentre trial, 750 women with the polycystic ovary syndrome were randomly assigned in a 1:1 ratio to letrozole or clomiphene for up to five treatment cycles, and the primary outcome was live birth during the treatment period.13 Live births were 72 of 376 (19.1%) with clomiphene and 103 of 374 (27.5%) with letrozole (P = 0.007; rate ratio 1.44, 95% CI 1.10 to 1.87), and ovulation occurred in 688 of 1425 treatment cycles (48.3%) with clomiphene against 834 of 1352 (61.7%) with letrozole.13 Pregnancy loss did not differ significantly (30 of 103 pregnancies, 29.1%, with clomiphene and 49 of 154, 31.8%, with letrozole), twin pregnancy was 7.4% against 3.4%, and serious adverse events before conception on clomiphene were ovarian torsion in 1 of 355 women and hospitalization in 3 of 355.13 The authors wrote that the study "was underpowered to detect a significant between-group difference" in twin pregnancy and named "the relatively high dropout rate" as a potential weakness.13 The trial was supported by NICHD grants and the authors state that "Neither manufacturer had a role in the study"; Dr. Legro reported consulting fees from Ferring Pharmaceuticals, AstraZeneca and Euroscreen; Dr. Diamond consulting fees from EMD Serono and stock in Advanced Reproductive Care; and Dr. Santoro grant support from Bayer and stock options in MenoGeniX.13
Deeper analysis: Hohl and colleagues, 2025
Hohl and colleagues at the Universidade Federal de Santa Catarina in Brazil published this systematic review and meta-analysis of randomised trials in Archives of Endocrinology and Metabolism in 2025, registered in PROSPERO as CRD42024536930.3 Eligible trials compared clomiphene or enclomiphene with testosterone gel, hCG, anastrozole or placebo in adult men with baseline total testosterone of 300 ng/dL or less, and the pooled "SERM" arm combined both drugs.3 Ten studies with 819 patients were included, 374 (45.7%) assigned to SERM therapy and 205 (25%) to placebo.3 Against placebo, SERM therapy raised total testosterone (mean difference 273.76 ng/dL; 95% CI 191.87 to 355.66; I2 = 89%), LH (4.66 IU/L) and FSH (4.59 IU/L), while sperm concentration did not differ significantly (7.50 million/mL; 95% CI −20.01 to 35.02; p = 0.59).3 Against testosterone gel, the testosterone difference was not significant (5.41 ng/dL; 95% CI −43.44 to 54.27; p = 0.83).3 The authors rated the evidence for testosterone, LH and FSH against placebo as moderate-quality "due to wide confidence intervals of the pooled effect estimates and moderate to high heterogeneity".3 Their listed limitations were a unit-of-analysis error from two cross-over trials, high heterogeneity in some endpoints and that the analysis "remains underpowered with regard to safety endpoints".3 Hohl and colleagues rated two included trials, one of them Habous and colleagues, as having a high risk of bias from flaws in the randomisation process, and one, Helo and colleagues in 2015, as having some concerns from the selection of the reported result.3 Among the included trials' safety reports, Hohl and colleagues list two deaths in the Kim trial of enclomiphene (one from a road accident, one from a stroke in the enclomiphene group with multiple pre-existing risk factors) and one pneumonia-related death in the placebo group of the Soares trial.3 The article text on PubMed Central contains no funding or conflict-of-interest statement.3
Deeper analysis: Saffati and colleagues, 2024
Saffati and colleagues at Baylor College of Medicine reported in Translational Andrology and Urology in 2024 that they "retrospectively studied patients at our academic center who had been prescribed clomiphene and, later, enclomiphene for hypogonadism".17 The 66 men had a mean age of 38.45 years, 78% had secondary hypogonadism, and median treatment was 18.7 months on clomiphene and 8.9 on enclomiphene.17 Median testosterone change was 98 ng/dL on clomiphene and 166 ng/dL on enclomiphene (P = 0.20), and median estradiol change was 17.5 against −5.92 pg/mL (P = 0.001).17 Overall side effects were reported by 31 men (47%) on clomiphene and 8 (13.8%) on enclomiphene (P = 0.001), with decreased libido in 33.3% against 8.6%, decreased energy in 16.7% against 5.2%, mood changes in 9.1% against none, and erectile dysfunction in 18.2% against 8.6% (P = 0.12).17 The authors listed as limitations a single institution, a small sample, patients with mental health conditions not being excluded, and "the absence of a washout period between clomiphene and enclomiphene treatments".17 The article states "Funding: None"; two authors list consulting for companies including AbbVie, Endo Pharmaceuticals and Tolmar, and the other authors declare no conflicts.17
Doses reported in studies and on labels
The app's typical dose range is 10 to 50 mg/day. Among the doses the label and studies above report, the range runs from 25 mg every other day in Katz and colleagues' study to 50 mg daily in the label and several trials, with a second label course of 100 mg daily and a maximum of 150 mg daily in the 2014 trial; none of the reported doses is 10 mg.1,11,13
| Source | Dose | Frequency | Length |
|---|---|---|---|
| Clomid label1 | 50 mg; 100 mg for a second course if ovulation does not appear to occur | Daily | 5 days a course |
| Legro and colleagues, 201413 | 50 mg, up to 150 mg | Daily, starting on cycle day 3 | 5 days a cycle, up to 5 cycles |
| Habous and colleagues, 201814 | 50 mg | 50 mg per day, per the meta-analysis table3 | 3 months |
| Helo and colleagues, 201510 | 25 mg | Daily | 12 weeks |
| Soares and colleagues, 201815 | 50 mg | Daily, per the meta-analysis table3 | 12 weeks |
| Pelusi and colleagues, 201716 | 25 mg, with metformin 2 g/day | Daily | 3 months a period, 6-week wash-out |
| Katz and colleagues, 201211 | 25 mg, titrated to 50 mg | Every other day | Mean 19 months |
| Mogar and colleagues, 202518 | 50 mg | 3 days a week | At least 3 months |
Side effects reported
From the label
The label's table of adverse events in clinical studies (n = 8029, which it notes includes 498 patients whose reports may have been duplicated) lists ovarian enlargement 13.6%, vasomotor flushes 10.4%, abdominal-pelvic discomfort, distention or bloating 5.5%, nausea and vomiting 2.2%, breast discomfort 2.1%, visual symptoms 1.5%, headache 1.3% and abnormal uterine bleeding 1.3%.1 The label states that "Clomiphene citrate, at recommended dosages, is generally well tolerated. Adverse reactions usually have been mild and transient and most have disappeared promptly after treatment has been discontinued".1 It also states that visual symptoms "increase in incidence with increasing total dose or therapy duration", that cases of prolonged visual disturbance have been reported, some after discontinuation, and that for ovarian hyperstimulation syndrome "Death due to hypovolemic shock, hemoconcentration, or thromboembolism has occurred".1 Among reported pregnancies in the label's clinical trials, "the incidence of multiple pregnancies was 7.98%", of which 6.9% were twin.1 On ovarian cancer, the label states that it "has been infrequently reported in patients who have received fertility drugs", that infertility is "a primary risk factor for ovarian cancer", and that epidemiology data "suggest that prolonged use of clomiphene may increase the risk of a borderline or invasive ovarian tumor".1 On males, it states that "testicular tumors and gynecomastia have been reported in males using clomiphene" and that the cause and effect relationship between reports of testicular tumors and the drug "is not known".1
In studies in men
Krzastek and colleagues reported that of men treated for more than 3 years, 8% reported side effects (mood changes in 5, blurred vision in 3, breast tenderness in 2) and "There was no significant adverse event in any patient".2 Hohl and colleagues summarise Soares and colleagues' trial as showing similar adverse event rates on clomiphene and placebo, with two placebo-group men stopping treatment (one for severe headache, one who died of pneumonia) and none on clomiphene, somnolence in 5 men on clomiphene against none on placebo (p = 0.064), and a significant rise in PSA within the normal range on clomiphene.3 Soares and colleagues also reported that clomiphene reduced HDL (P < 0.001).15 In a retrospective review of 20 men aged 27 to 76, 15 of whom had had space-occupying lesions of the pituitary, given clomiphene 50 mg three days a week for at least 3 months, Mogar and colleagues (Journal of the Endocrine Society, 2025) reported a fall in serum IGF-1 in 15 (75%; median change 0.60 SD downward), to more than 2 SD below the age and sex mean in 2, and a rise in 3.18 In a retrospective multi-institutional comparison, Wheeler and colleagues found polycythemia in 1.7% of 188 men on clomiphene against 11.2% of 175 on testosterone replacement (p = 0.0003), with the testosterone group older (51.5 against 38 years) and treated for longer (19.6 against 9.2 months).19
Bloodwork and markers
Sources in this part
The app lists total testosterone, free testosterone, estradiol, LH and FSH as the markers for this compound. Hohl and colleagues' pooled differences against placebo, for clomiphene and enclomiphene trials together, were 273.76 ng/dL for total testosterone, 4.66 IU/L for LH and 4.59 IU/L for FSH.3 Estradiol also rose: Krzastek and colleagues reported it "was significantly increased", and Saffati and colleagues a median change of 17.5 pg/mL on clomiphene.2,17
Regulatory and anti-doping status
Sources in this part
The Clomid label (Cosette Pharmaceuticals, revised 08/2023) states the indication as ovulatory dysfunction in women desiring pregnancy and lists contraindications including pregnancy, liver disease and abnormal uterine bleeding of undetermined origin.1 The WADA 2026 Prohibited List, in force from 1 January 2026, lists clomifene under S4.2, anti-estrogenic substances (anti-estrogens and selective estrogen receptor modulators), in class S4, hormone and metabolic modulators, prohibited at all times in and out of competition.4 The list adds that "Prohibited substances in classes S4.1 and S4.2 are Specified Substances" and that S4 substances may be found in medications used for, among others, infertility (female) and polycystic ovarian syndrome.4
Storage and handling
Sources in this part
The Clomid label describes 50 mg off-white tablets and states a storage temperature of "15° to 30°C (59° to 86°F)", with protection from heat, light and excessive humidity and closed containers.1
What is not known
The label and the PubMed entries for the Mikkelson and Ghobadi papers give no half-life figure for zuclomiphene, and Ghobadi and colleagues could not determine a conventional model for the isomers.1,7,5 The label states that there are no adequate or well-controlled studies of effectiveness in male infertility, and Hohl and colleagues describe their meta-analysis as "underpowered with regard to safety endpoints".1,3 Several of the men's studies were retrospective, such as the 20 men in the IGF-1 report and the 400 men in the long-term safety study.18,2
Frequently asked questions
What is the half-life of clomiphene (Clomid)?
The app's figure for the half-life of clomiphene is about 7 days (168 hours), while the Clomid label gives no figure and states that zuclomiphene has a longer half-life than enclomiphene.1 Ghobadi and colleagues wrote that a conventional pharmacokinetic model of the isomers could not be determined because of a very flat terminal half-life.5
What is Clomid used for according to its label?
Is clomiphene banned by WADA?
Yes, clomifene is named in class S4.2, anti-estrogenic substances, on the WADA 2026 Prohibited List, a class prohibited at all times in and out of competition.4
What is the difference between clomiphene, enclomiphene and zuclomiphene?
What are the side effects of clomiphene in men?
The label lists testicular tumors and gynecomastia as reported in males using clomiphene, and states that the cause and effect relationship for the testicular tumor reports is not known.1 In a retrospective study of 66 men, Saffati and colleagues reported adverse effects in 47% on clomiphene and 13.8% on enclomiphene, with no washout between the two drugs.17 Krzastek and colleagues reported side effects in 8% of men treated for more than 3 years and no significant adverse event.2
Does clomiphene raise testosterone in men?
In the randomised trials cited, testosterone rose on clomiphene: Pelusi and colleagues reported, in 21 evaluable obese men with impaired glucose tolerance or type 2 diabetes who took metformin in both arms, 3.03 to 5.99 ng/mL against 2.87 to 3.09 ng/mL on placebo, and Hohl and colleagues' pooled analysis of 10 studies (819 men), clomiphene and enclomiphene trials together, gave a mean difference of 273.76 ng/dL against placebo (95% CI 191.87 to 355.66; I2 = 89%).16,3 Helo and colleagues found no significant change in semen parameters on clomiphene 25 mg/day over 12 weeks.10
How does clomiphene compare with letrozole in polycystic ovary syndrome?
Guides, tools and comparisons
- Clomid dosage for menA guide that answers a question on this compound.
- Clomid vs enclomipheneA side-by-side with another compound.
- Previous in Post-cycle and ancillaries: Citrus BergamotThe compound before this one in the class.
- Next in Post-cycle and ancillaries: EnclomipheneThe compound after this one in the class.
References
- Cosette Pharmaceuticals. Clomid (clomiphene citrate) tablets, USP: prescribing information. DailyMed, revised 08/2023. DailyMed label
- Krzastek SC, Sharma D, Abdullah N, et al. Long-term safety and efficacy of clomiphene citrate for the treatment of hypogonadism. J Urol 2019. PMID 31216250
- Hohl A, Chavez MP, Pasqualotto E, et al. Clomiphene or enclomiphene citrate for the treatment of male hypogonadism: a systematic review and meta-analysis of randomized controlled trials. Arch Endocrinol Metab 2025. PMC12510335
- World Anti-Doping Agency. The Prohibited List, World Anti-Doping Code International Standard, in force 1 January 2026. WADA Prohibited List 2026
- Ghobadi C, Mirhosseini N, Shiran MR, et al. Single-dose pharmacokinetic study of clomiphene citrate isomers in anovular patients with polycystic ovary disease. J Clin Pharmacol 2009. PMID 19033451
- Wiehle R, Cunningham GR, Pitteloud N, et al. Testosterone restoration using enclomiphene citrate in men with secondary hypogonadism: a pharmacodynamic and pharmacokinetic study. BJU Int 2013. PMC4155868
- Mikkelson TJ, Kroboth PD, Cameron WJ, et al. Single-dose pharmacokinetics of clomiphene citrate in normal volunteers. Fertil Steril 1986. PMID 3091405
- Murdter TE, Kerb R, Turpeinen M, et al. Genetic polymorphism of cytochrome P450 2D6 determines oestrogen receptor activity of the major infertility drug clomiphene via its active metabolites. Hum Mol Genet 2012. PMID 22108178
- Helo S, Mahon J, Ellen J, et al. Serum levels of enclomiphene and zuclomiphene in men with hypogonadism on long-term clomiphene citrate treatment. BJU Int 2017. PMID 27511863
- Helo S, Ellen J, Mechlin C, et al. A randomized prospective double-blind comparison trial of clomiphene citrate and anastrozole in raising testosterone in hypogonadal infertile men. J Sex Med 2015. PMID 26176805
- Katz DJ, Nabulsi O, Tal R, Mulhall JP. Outcomes of clomiphene citrate treatment in young hypogonadal men. BJU Int 2012. PMID 22044663
- Legro RS, Barnhart HX, Schlaff WD, et al. Clomiphene, metformin, or both for infertility in the polycystic ovary syndrome. N Engl J Med 2007. PMID 17287476
- Legro RS, Brzyski RG, Diamond MP, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med 2014. PMID 25006718
- Habous M, Giona S, Tealab A, et al. Clomiphene citrate and human chorionic gonadotropin are both effective in restoring testosterone in hypogonadism: a short-course randomized study. BJU Int 2018. PMID 29772111
- Soares AH, Horie NC, Chiang LAP, et al. Effects of clomiphene citrate on male obesity-associated hypogonadism: a randomized, double-blind, placebo-controlled study. Int J Obes 2018. PMID 29777228
- Pelusi C, Giagulli VA, Baccini M, et al. Clomiphene citrate effect in obese men with low serum testosterone treated with metformin due to dysmetabolic disorders: a randomized, double-blind, placebo-controlled study. PLoS One 2017. PMC5590732
- Saffati G, Kassab J, Orozco Rendon D, et al. Safety and efficacy of enclomiphene and clomiphene for hypogonadal men. Transl Androl Urol 2024. PMC11491226
- Mogar N, Zhang D, Heaney AP. Reduced IGF-1 levels following clomiphene treatment for male hypogonadism. J Endocr Soc 2025. PMC12105911
- Wheeler KM, Smith RP, Kumar RA, et al. A comparison of secondary polycythemia in hypogonadal men treated with clomiphene citrate versus testosterone replacement: a multi-institutional study. J Urol 2017. PMID 27984109